Alivus Life Sciences Ltd Share Price
(ALIVUS)
₹1081.15▲1.84%
as on 04:01PM, 28 Mar 2025
Day's Low
Day's High
52 Week's Low
52 Week's High
Returns % | |
1 Month Return | + 19.97 % |
3 Month Return | + 9.49 % |
1 Year Return | + 36.7 % |
Market Stats | |
Previous Close | ₹1,061.65 |
Open | ₹1,093.00 |
Volume | 3.86L |
Upper Circuit | ₹1,273.95 |
Lower Circuit | ₹849.35 |
Market Cap | ₹13,009.15Cr |
P/E Ratio
0PEG Ratio
0Market Cap
₹13,009.15 Cr
P/B Ratio
4.07
EPS
0Dividend Yield
0Sector
Pharmaceuticals
ROE
21.07
based on 5 analysts
83.33%
Buy
16.67%
Hold
0.00%
Sell
Based on 5 analysts offering long term price targets for Glenmark Life Sciences. An average target of ₹1296
Source: S&P Global Market Intelligence
Glenmark Life Sciences price forecast by 5 analysts
Upside of22.07%
High
₹1360
Target
₹1296.00
Low
₹1150
Glenmark Life Sciences target price ₹1296, a slight upside of 22.07% compared to current price of ₹1081.15. According to 5 analysts rating.
Excluding Excise Duty and Other Income, represents Net Revenue
Glenmark Life Sciences revenue growth forecast
Expected growth rate Q1, FY2027:0
Forecast
Actual
Including amortisation and stock based compensations
Glenmark Life Sciences EPS growth forecast
EPS estimate Q1, FY2027:0
Forecast
Actual
Source: S&P Global Market Intelligence
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
Retail Holding Up
Retail Investor have increased holdings from 12.98% to 13.40% in Dec 2024 quarter
MF Holding Up
Mutual Funds have increased holdings from 2.82% to 3.23% in Dec 2024 quarter
Price Rise
In the last 1 month, ALIVUS stock has moved up by 20.0%
Against Peers
In the last 1 year, Divis Laboratories Ltd has given 70.5% return, outperforming this stock by 33.8%
Promoter Holding Unchanged
Promoters holdings remained unchanged at 75.00% of holdings in Dec 2024 quarter
Against Peers
In the last 3 years, Torrent Pharmaceuticals Ltd has given 137.0% return, outperforming this stock by 20.1%
FII Holding Down
Foreign Institutions have decreased holdings from 7.85% to 6.74% in Dec 2024 quarter
Investors | Holdings % | FY Quarter | 3M change |
---|---|---|---|
Promoter Holdings | 75% | 0.00 | |
Foreign Institutions | 6.74% | ||
Mutual Funds | 3.23% | 14.49 | |
Retail Investors | 13.4% | 3.23 | |
Others | 1.63% | 21.28 |
Alivus Life Sciences Ltd’s net profit jumped 15.32% since last year same period to ₹136.96Cr in the Q3 2024-2025. On a quarterly growth basis, Alivus Life Sciences Ltd has generated 43.68% jump in its net profits since last 3-months.
Read More about Earnings ResultsIn the quarter ending September 2023, Alivus Life Sciences Ltd has declared dividend of ₹22.50 - translating a dividend yield of 4.02%.
Read More about DividendsBearish
Neutral
Bullish
Alivus Life Sciences Ltd is currently in a Bullish trading position according to technical analysis indicators.
Company | Analyst View | Market Cap | 5 Year CAGR | Debt to Asset Ratio | Net Profit | Yearly Revenue |
---|---|---|---|---|---|---|
BUY | ₹13,009.15 Cr | 8.37% | 0.51 | NA | NA | |
NA | ₹236.89 Cr | 278.53% | 0.58 | -₹12 Cr | ₹15 Cr | |
NA | ₹3,516.02 Cr | 68.2% | 0.58 | -₹154 Cr | ₹2,615 Cr | |
NA | ₹3,325.20 Cr | 126.56% | 0.70 | ₹86 Cr | ₹806 Cr | |
NA | ₹41.74 Cr | 11.19% | 0.51 | ₹1 Cr | ₹62 Cr |
Organisation | Glenmark Life Sciences |
Headquarters | |
Industry | Pharmaceuticals |
E-voting on shares | Click here to vote |
Alivus Life Sciences Ltd share price today stands at ₹1081.15, Open: ₹1093, Previous Close: ₹1061.65, High: ₹1139.4, Low: ₹1066, 52 Week High: ₹1335.1, 52 Week Low: ₹741.85.
Today's traded volume of Alivus Life Sciences Ltd(ALIVUS) is 3.86L.
Today's market capitalisation of Alivus Life Sciences Ltd(ALIVUS) is ₹13009.15Cr.
Alivus Life Sciences Ltd (ALIVUS) share price is ₹1081.15. It is down -19.02% from its 52 Week High price of ₹1335.1
Alivus Life Sciences Ltd (ALIVUS) share price is ₹1081.15. It is up 45.74% from its 52 Week Low price of ₹741.85